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ABSTRACT
Multi-targeted tyrosine kinase inhibitors (TKIs) have broad efficacy and similar
FDA-approved indications, suggesting shared molecular drug targets across cancer
types. Irrespective of tumor type, 20-30% of patients treated with multi-targeted TKIs
demonstrate intrinsic resistance, with progressive disease as a best response. We
conducted a retrospective cohort study to identify tumor (somatic) point mutations,
insertion/deletions, and copy number alterations (CNA) associated with intrinsic
resistance to multi-targeted TKIs. Using a candidate gene approach (n=243), tumor
next-generation sequencing and CNA data was associated with resistant and nonresistant outcomes. Resistant individuals (n=11) more commonly harbored somatic
point mutations in NTRK1, KDR, TGFBR2, and PTPN11 and CNA in CDK4, CDKN2B,
and ERBB2 compared to non-resistant (n=26, p<0.01). Using a random forest
classification model for variable reduction and a decision tree classification model,
we were able to differentiate intrinsically resistant from non-resistant patients. CNA
in CDK4 and CDKN2B were the most important analytical features, implicating the
cyclin D pathway as a potentially important factor in resistance to multi-targeted TKIs.
Replication of these results in a larger, independent patient cohort has potential to
inform personalized prescribing of these widely utilized agents.

than site of origin, which has translated into the ability to
predict drug response utilizing tumor genetics rather than
tumor type (i.e., histology or site of origin) in some instances
[1]. For example, using multiple genetic platforms, The

INTRODUCTION
Increasing evidence supports the classification of
tumors based on genetic and molecular characteristics rather
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Cancer Genome Atlas Research Network defined four
molecular subtypes of breast cancer (Luminal A, Luminal B,
HER2-enriched, and Basal-like) and found that one subtype
(Basal-like) is more similar to serous ovarian cancer than to
other breast cancers [2]. Further analysis showed that, due
to their molecular similarities, Basal-like breast cancers
and serous ovarian cancers are likely susceptible to similar
targeted treatments. In another multiplatform analysis of
twelve tissue-defined cancer types, eleven major subtypes
were identified, with only five subtypes corresponding to
their tissue of origin, and the remaining six subtypes being
shared by distinct cancer types (e.g., lung squamous, head
and neck, and some bladder cancers fell into a single subtype)
[3]. Studies such as these have influenced clinical cancer drug
development. The classification and treatment of tumors
based on molecular alterations is currently being studied
through the use of basket trials, such as NCI-MATCH and
NCI-MPACT, which randomize patients to an individualized
targeted therapy arm or a non-pathway-specific arm
independent of tumor histology [4]. We hypothesize that
genetic alterations within tumors, regardless of site of origin
or histology, can be used as a biomarker of response to
targeted anticancer therapies.
The broad efficacy of multi-targeted tyrosine kinase
inhibitors (TKIs) across tumor types suggests similarities
in the genetics of the tumors they are used to treat. The
multi-targeted TKIs (i.e., axitinib, cabozantinib, pazopanib,
regorafenib, sorafenib, sunitinib, and vandetanib) currently
have FDA-approved indications in seven histological
tumor types, and are used off-label in additional solid and
hematologic malignancies. While the clinical trials of these
agents demonstrated overall efficacy, a substantial number
of individuals never responded to therapy. This is a clinical
challenge for most targeted anticancer agents [5]. In the
pivotal phase III clinical trials that led to approval of each of
the multi-targeted TKIs, approximately 20 to 30% of patients
showed a best response of progressive disease, demonstrating
intrinsic resistance [6–13]. In an exploratory study (n=262)
examining intrinsic resistance to multi-targeted TKIs across
tumor types, we observed an intrinsic resistance rate of 21%,
consistent with that seen in clinical trials (unpublished data).
No patient demographic or clinical factors (e.g., tumor type or
drug received) were associated with intrinsic resistance. This
supports the hypothesis that genetic factors may be important
in predicting intrinsic resistance to the multi-targeted TKIs.
We conducted a retrospective case-control study using a
candidate gene approach to identify somatic point mutations,
insertions/deletions, and copy number alterations (CNAs)
associated with resistance to multi-targeted TKIs across
tumor types.

majority of individuals were white (88%) non-Hispanic
(90%) males (72%). The most common tumor types being
treated were sarcoma (48%) and renal cell carcinoma
(40%), as would be expected, and the majority of patients
received pazopanib (38%), followed by sorafenib (30%)
and sunitinib (28%). One patient received regorafenib
and one axitinib. Of the 50 patients included, 11 (22%)
were classified as resistant, 26 (52%) as non-resistant, and
13 had unclassifiable responses. This corresponded to an
overall resistance rate of 30.5% (11/36) observed in our
cohort. After correcting for multiple comparisons using
false discovery rate (FDR), there were no statistically
significant differences in the demographic and clinical
characteristics of resistant and non-resistant patients.
Resistant patients discontinued multi-targeted TKIs
significantly sooner than non-resistant patients did (U =
14.5, p <0.0001, Figure 1).

Next-generation sequencing: quality control
A total of 24 samples underwent targeted exome
sequencing under the TCC protocol. The target region was
1,321 genes covering 3.8 Mb. The median number of reads
aligned per sample was 15,283,830. Median read depth of
coverage was 141x. A median of 93.7% of coding bases
were covered at least 10x across samples. For the 25 tumor
samples that underwent WES, an average coverage of 151x
(95% CI 140 - 163) per base was achieved. The average
total number of reads per sample was 1.83 x 108 (95% CI
1.75 x 108 - 1.92 x 108) or 91.5 million paired-end reads,
with an average of 20% duplicate reads and 98% of reads
mapped to the human reference genome. After removing
duplicates, paired-end reads were properly paired overall
(average per sample 94%). An average of 74,349 variants
(point mutations and insertion/deletions) were detected per
sample, of which 22,993 (31%) were within coding regions
of the genome, and 11,590 (16%) were non-synonymous
variants. There were five genes (CDK12, FGFR4, MLL2,
LRP1B, and ARAF) with significant variation by sequencing
method (FDR-corrected p-values all <0.005), warranting
exclusion from further analyses. Four genes (BRCA2,
CDK12, MLL2, and VHL) were differentially mutated
(p-value < 0.05) between renal cell carcinoma patients
and sarcoma patients; however, these differences were not
significant when correcting for multiple comparisons (FDR
q-values >0.5).

Next-generation sequencing: genetic associations
We identified four genes (NTRK1, KDR, TGFBR2,
and PTPN11) more commonly mutated in resistant
patients than non-resistant patients (Figure 2A). The
finding with the lowest p-value was NTRK1, in which 3
(30%) resistant patients carried somatic coding mutations
(2 point mutations and 1 splice site variant) versus zero
non-resistant patients (p = 0.02). Nonsynonymous coding
mutations in KDR, PTPN11, and TGFBR2 were present

RESULTS
Patient population and phenotypes
A total of 50 unique patients were included in this
study (Table 1). The average age was 60 years old and the
www.impactjournals.com/oncotarget
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Table 1: Patient demographics (n = 49). Demographics are broken down by phenotype for individuals who underwent
next-generation sequencing (n=37) and copy number alteration analysis (n=29)
Next-generation sequencing
Characteristic

All
patients
(n = 50)

Resistant
Non(n = 11) resistant
(n = 26)

Age*

Resistant
(n = 8)

Non-resistant
(n = 21)

0.19
60.2 ± 12

55.2 ±
13.1

61.2 ±
12.6

Median

62

61

Range

34 – 80

36 – 70

Mean ± SD

P-value
(FDR)#

Copy number alteration

0.06
52.9 ±
13.9

63.1 ± 11.3

62.0

58.5

66

34 – 80

36 – 68

39 – 80

Sex

(0.39)

0.05

Male

36 (72)

7 (63.6)

24 (92.3)

Female

14 (28)

4 (36.3)

2 (7.7)

Race

(0.15)

44 (88)

10 (90.9)

24 (92.3)

Black

3 (6)

1 (9.1)

Asian

2 (4)

Unknown

1 (2)

4 (50)

19 (90.5)

4 (50)

2 (9.5)
21 (100)

0

1 (12.5)

0

0

1 (3.8)

0

0

0

1 (3.8)

0

0

1.0 (1.0)
5 (10)

1 (9.1)

3 (11.5)

1 (12.5)

1 (4.8)

Non-Hispanic

45 (90)

10 (90.9)

23 (88.5)

7 (87.5)

20 (95.2)

0.03

Sarcoma

24 (48)

6 (54.5)

9 (34.6)

Renal cell
carcinoma

20 (40)

2 (18.2)

Hepatic

3 (6)

Breast

5 (23.8)

16 (61.5)

1 (12.5)

15 (71.4)

1 (9.1)

1 (3.8)

1 (12.5)

1 (4.8)

1 (2)

1 (9.1)

0

1 (12.5)

0

Colorectal

1 (2)

1 (9.1)

0

1 (12.5)

0

Melanoma

1 (2)

0

0

0

0

0.44

Pazopanib

19 (38)

5 (45.5)

7 (26.9)

Sorafenib

15 (30)

3 (27.3)

Sunitinib

14 (28)

Axitinib
Regorafenib

(0.66)

(0.48)
0.007

4 (50)

Multi-targeted
TKI

(0.15)

(0.33)

0.48

Hispanic
Cancer type

(0.07)
0.27

7 (87.5)

Ethnicity

(0.80)

(0.09)

0.03

0.66

White

P-value (FDR)#

(0.04)

0.03
4 (50)

4 (19.0)

10 (38.5)

3 (37.5)

9 (42.9)

2 (18.2)

8 (30.8)

0

8 (38.1)

1 (2)

0

1 (3.8)

0

0

1 (2)

1 (9.1)

0

1 (12.5)

0

(0.07)

Age represents the age at multi-targeted TKI initiation.
P-value for continuous variables represents the logistic regression p-value and categorical data was compared between
resistant and non-resistant individuals using Fisher’s exact test. FDR represents the FDR-corrected p-value.
*
#
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Figure 1: Time to multi-targeted tyrosine kinase inhibitor discontinuation. Data represents mean and standard deviation.
Mann-Whitney U p-value < 0.0001.

**

Figure 2: Differences in next-generation sequencing variants. (A) OncoPrint of somatic nonsynonymous point mutations and
insertions/deletions observed differentially by phenotype. (B) Distribution of somatic nonsynonymous point mutations or splice site
variants in the four key genes.
www.impactjournals.com/oncotarget
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Decision tree for combined data

in two (20%) resistant patients and zero non-resistant
patients (p = 0.08). Altogether, 55% of resistant patients
harbored mutations in one or more of these genes, while
zero non-resistant patients carried mutations in these genes
(Fisher’s exact p-value = 0.0002, Figure 2B). Gene set
enrichment identified trends of receptor binding, activity,
protein kinase, tyrosine, and transmembrane within the
top gene hits. Of the four top hits, KDR and PTPN11
were included in screening 1,001 cancer cell lines in the
Genomics in Drug Sensitivity in Cancer database [14, 15].
Presence of KDR mutations was consistently predicted to
confer resistance to multi-targeted TKIs, while presence of
PTPN11 mutations tended to predict sensitivity to multitargeted TKIs.

The most informative CNA and next-generation
sequencing features from the random forest classification
model were used to generate a decision tree for identifying
resistant individuals. After quality control, data for 29
individuals with sequencing and CNA results were
included in the construction of the final tree. Five genes
(CDKN2B, CDK4, TGFBR2, EPHA3, and TNFAIP3) were
identified as important for differentiating resistant from
non-resistant individuals and were selected as features
in the final decision tree (Figure 4). CNA in CDKN2B
and CDK4 were the most informative and explained
responses for 55% (16/29) of the population. Interestingly,
in measuring the importance of variables using the mean
decrease in Gini score, all gene hits from individual
sequencing (NTRK1, KDR, TGFBR2, and PTPN11)
and CNA (CDK4, CDKN2B, and ERBB2) analysis
were identified as being amongst the most informative
variables (Figure 4, Supplementary Table 2). The decision
tree model resulted in a high sensitivity and specificity
for differentiating resistant individuals (0.75 and 1,
respectively; balanced accuracy 0.88); however, leaveone-out cross-validation (LOOCV) resulted in a lower
sensitivity and specificity (0.25 and 0.95, respectively;
balanced accuracy 0.6), indicating that the model
constructed on all of the data is overfitting. Although the
sensitivity dropped substantially after LOOCV, model
specificity remained high, suggesting these features are
robustly able to distinguish non-resistant samples in this
rather small cohort. It further suggested that having the
identified combination of mutations increases one’s odds
of being resistant (OR 6.67), however this result was not
statistically significant (p>0.05). These features may be
good candidates for follow-up analysis, but extensive
external validation and larger sample sizes will be needed
to develop a more clinically relevant predictive model.

Copy number alterations
Somatic CNA data was generated for 29
individuals, of which 8 (27.6%) were classified as
resistant. All samples resulted in data that met prespecified quality control criteria. Individuals exhibited
a diverse range of somatic CNAs, with some individuals
demonstrating much more genomic instability than
others. A total of 55 (22.6%) genes harbored CNAs
that met specified filtering criteria (Figure 3). No genes
met the FDR-corrected significance level; however,
three genes (CDK4, CDKN2B, and ERBB2) met the
exploratory cut-off (FDR-corrected p < 0.3). CNAs
in CDKN2B were only observed in resistant patients,
while CNAs in CDK4 and ERBB2 were less common
in resistant patients (only non-resistant patients harbored
CNAs in ERBB2). All of the CNAs in CDKN2B and
ERBB2 were homozygous losses, and the majority
(14/16, 87.5%) of aberrations in CDK4 were also losses.
Gene set enrichment identified cancer pathways, cyclin,
and kinase as network trends between the three gene hits
for CNA.

Figure 3: Copy number alterations (CNAs) observed by phenotype. *Genes that met pre-specified cut-off for exploratory hits
(i.e., differential CNAs between resistant and non-resistant individuals).
www.impactjournals.com/oncotarget

115118

Oncotarget

DISCUSSION

of acquired resistance to the multi-targeted TKIs [17].
In a recent retrospective analysis of archived renal cell
carcinoma patients treated with sunitinib, Stubbs and
colleagues found no association between KDR expression
and overall or progression-free survival, but did not assess
mutations [18]. However, a retrospective study of 275
sarcoma patients identify a significant correlation between
high VEGFR2 protein expression and decreased patient
survival (p <0.001) [19].
The most common NTRK1 alterations observed in
cancer are gene fusions; however, point mutations have
also been reported in numerous solid tumors [20, 21].
Multiple studies have linked NTRK1 overexpression to
tumor progression and poor outcomes in solid cancers
[22–24], and NTRK1 mutations confer acquired resistance
to NTRK inhibitors [25]. Somatic mutations of TGFBR2
are commonly observed across solid tumor types [20,
21]. The majority of studies exploring the clinical
significance of TGFBR2 mutations are in the context
of breast cancer, where high expression of TGFBR2
is associated with tumor metastasis and response to
chemotherapy [26–28]. Associations between somatic
TGFBR2 alterations and cancer progression occur in a
range of solid tumor types, including gastric, bladder, and
squamous cell carcinoma [29–31]. PTPN11 mutations are
most commonly associated with Noonan syndrome and
juvenile myelomonocytic leukemia; however, activating
somatic mutations have been observed in solid tumors,

We conducted a retrospective candidate gene study
to identify somatic point mutations and copy number
alterations associated with intrinsic resistance to multitargeted TKIs. Using next-generation sequencing, we
identified four genes commonly mutated in resistant
patients, but not mutated in non-resistant patients:
NTRK1, KDR, TGFBR2, and PTPN11. Interestingly, three
of the four top hits (TGFR, KDR, and NTRK1) encode
transmembrane protein kinases that are known targets of
multi-targeted TKIs to varying degrees. The final gene,
PTPN11, encodes SHP2, a tyrosine phosphatase that
mediates signaling of oncogenic tyrosine kinases, such as
Ras-ERK-AKT signaling pathways.
All four of the top gene hits from sequencing
analysis are known to be mutated in cancer patients and
have some literature suggesting possible associations with
resistance and/or prognosis. KDR encodes the vascular
endothelial growth receptor 2 (VEGFR2), a tyrosine kinase
that mediates VEGF-induced endothelial proliferation,
survival, and migration. KDR is commonly mutated across
cancer types, and is one of the primary targets of the multitargeted TKIs, with up to eighty percent of activity being
inhibited by TKIs [16]. Therefore, mutations in the gene
encoding VEGFR2 represent a plausible mechanism of
resistance to these agents. In fact, escape from VEGFR2
signaling dependency has been proposed as a mechanism

Figure 4: Decision tree for differentiating resistant from non-resistant patients. Branches represent decisions based on genes
identified as influential in differentiating phenotypes. A loss represents a homozygous copy number loss; a gain represents a copy number
gain greater than seven; a mutation represents any non-synonymous or missense mutation in a coding region of the gene.
www.impactjournals.com/oncotarget
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including colorectal, breast, and renal cell carcinomas
[20, 21]. These mutations enhanced cancer progression,
invasion, and metastasis [32–34] and were associated with
decreased response rates in hepatocellular carcinoma,
glioma, and gastric cancers [32, 35, 36]. In an elegant
in vitro study that utilized colon and melanoma cancer
cells, Prahallad and colleagues demonstrated that PTPN11
activating mutations were present in the setting of both
intrinsic and acquired resistance and that inhibition
of PTPN11 is lethal in cancer cells driven by activated
tyrosine kinases [37].
We identified three genes (CDK4, CDKN2B, and
ERBB2) with differential patterns of CNAs between
resistant and non-resistant patients. Interestingly, CDK4
and CDKN2B both encode for proteins involved in the
cyclin-dependent (cyclin D) pathway, which regulates
progression through the cell cycle. The cyclin D pathway
is commonly dysregulated in solid malignancies
through somatic copy number alterations [38]. In our
cohort, we observed a higher frequency of CDKN2B
losses in resistant patients, while non-resistant patients
more commonly harbored losses in CDK4 (Figure 5).
Biologically, CDK4 functions as a positive regulator of
the cell cycle, while CDKN2B is a negative regulator.
Therefore, loss of CDK4 results in cell cycle arrest and
tumor cell senescence, while loss of CDKN2B maintains

cell cycle progression and tumor cell growth. The CNAs
observed in our cohort suggest that cyclin D regulation
may serve as an important secondary or bypass track
for cancer progression in individuals treated with multitargeted TKIs. In fact, reduced expression of CDKN2A
(a tumor suppressor protein similar to CDKN2B), has
been observed in sarcoma progression and correlated with
reduced patient survival [39]. ERBB2 encodes HER2, a
transmembrane tyrosine kinase that regulates the PI3K/
AKT pathway upstream of mTOR. Interestingly, after
therapeutic failure with multi-targeted TKIs, mTOR
inhibitors are recommended as treatment options. We
observed that patients non-resistant to multi-targeted TKIs
more commonly harbored ERBB2 losses, which suggests
that mTOR may not be overregulated in these individuals,
but perhaps is an important mechanism of tumorigenesis
in the resistant patients.
The combination of using random forest
classification models for variable reduction and
constructing a decision tree using the combined nextgeneration sequencing and CNA results generated a
translatable model. The genetic alterations that were
identified as being most informative were CNAs in
CDKN2B and CDK4, further supporting a potential roll
of the cyclin D pathway in resistance to multi-targeted
TKIs. EPHA3 and TNFAIP3 were identified as important

Figure 5: Copy number alterations (CNAs) in the cyclin-dependent (cyclin D) pathway may regulate progression
through the cell cycle. The cyclin D pathway regulates progression through the cell cycle, ultimately regulating cell division (mitosis,
or M phase). The CNAs in genes relevant to this pathway may modulate cell cycle progression as depicted in the figure.
www.impactjournals.com/oncotarget
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plausibility; however, we acknowledge that multiple
other factors may be important in determining who will
respond to these agents. For example, pharmacokinetics
and pharmacodynamics may affect drug penetration and
exposure. Using MALDI-MSI (matrix-assisted laser
desorption ionization mass spectrometry imaging) to
visualize the distribution patterns of multi-targeted TKIs
in mouse models, Torok and colleagues determined that
poor drug penetration in some tumors resulted in primary
resistance [47]. Clinical variability in drug concentrations,
despite receiving the same dose, was associated with
variability in side effects and survival outcomes [48, 49].
Lysosomal sequestration has also been demonstrated
to confer resistance to the multi-targeted TKIs [50, 51]
and was associated with conferring cross-resistance to
the multi-targeted TKIs [52]. Finally, germline genetics
in drug transporters, such as ABCB1 and ABCG2, or
pharmacodynamic proteins, such as BIM, may also
influence response to these agents [53–55]. While many
factors must be considered when developing an optimized
algorithm for predicting resistance in clinical practice, this
study identified a combination of mutations and CNA that
were associated with resistance to multi-targeted TKIs. With
additional validation, preemptive identification of patients
intrinsically resistant to multi-targeted TKIs will inform
personalized treatment decisions to maximize outcomes
while avoiding unnecessary exposures and toxicities.

based on the random forest classification model, but were
not identified in separate next-generation sequencing or
CNA analyses; however, both of these genes have been
previously associated with prognosis and resistance.
EPHA3 encodes a protein tyrosine kinase receptor and its
expression has been associated with high invasive capacity
and poor overall survival in hepatocellular carcinoma,
gastric cancer, and glioblastoma [40–42]. Additionally,
EPHA3 has been associated with the regulation of multidrug resistance in small cell lung cancer via the PI3K/
BMX/STAT3 signaling pathway [43]. TNFAIP3 encodes
a zinc finger protein that serves as a tumor suppressor
through its potent inhibition of the NF-κB signaling
pathway [44]. TNFAIP3 has also been associated with
regulating drug resistance in multiple solid tumor
types [45, 46]. Therefore, dysregulation of these genes
represents a biologically plausible mechanism of intrinsic
resistance to multi-targeted TKIs.
While the decision tree explained our data well, it
appears to be overfitted based on the reduced performance
with LOOCV, indicating that additional research is needed
to develop a model that will be predictive of patient
outcomes. A larger cohort is needed to robustly predict
intrinsic resistance in independent datasets. Although this
model is not robust enough for clinical use, we believe
the five genes identified as being the most important for
distinguishing resistant samples are strong candidates for
additional follow-up analysis.
The most notable limitation of this study is the
sample size. To address this limitation, we elected to
use a candidate gene approach to decrease the multiple
testing burden. While this was a good method for
increasing statistical power, limitations to the candidate
gene approach exist, with the main disadvantage being
the inability to identify completely novel or unexpected
findings. However, the complete paucity of data on
resistance to multi-targeted TKIs and, even more-so,
intrinsic resistance to multi-targeted TKIs makes any
information novel and valuable to this field. Nevertheless,
the identification and collection of data from an
independent replication cohort would be invaluable to
the field. Another limitation of our study, inherent to its
retrospective design, was the use of samples collected
for clinical purposes as opposed to prospective collection
for research purposes. However, the samples included in
our study were all collected prior to multi-targeted TKI
initiation, with the exception of one. The one individual
with a sample collected after TKI treatment was
intrinsically resistant to sorafenib, and we believe that any
mutations that conferred intrinsic resistance would persist
during and after TKI treatment.
We conducted an exploratory study to identify
somatic point mutations, insertions/deletions, and copy
number alterations characteristic in individuals with
intrinsic resistance to multi-targeted TKIs. We identified
potential predictors of resistance that each have biological
www.impactjournals.com/oncotarget

MATERIALS AND METHODS
Patient population
Patients were identified from the Total Cancer Care
(TCC) cohort at Moffitt Cancer Center, an institutional review
board (IRB)-approved biobanking protocol (MCC14690,
MCC13579) in which individuals agree to provide tissue and
blood samples for research and to be followed throughout
their lifetime [56]. Additional Moffitt Cancer Center
Scientific Review Committee and IRB-approvals were
granted to access tissue samples and conduct this particular
study (MCC18790). Individuals eligible for study inclusion
were patients consented between January 1, 1994 and
December 31, 2015 over the age of 18 years diagnosed with
any type of solid tumor and treated with a multi-targeted TKI
(axitinib, cabozantinib, pazopanib, regorafenib, sorafenib,
sunitinib, or vandetanib). Individuals were included if they
had targeted exome sequencing or whole exome sequencing
(WES) data available through the TCC protocol or if a tumor
FFPE sample was available that could be used for DNA
extraction and WES. Individuals treated with a multi-targeted
TKI for a hematologic malignancy were excluded.

Phenotyping
Data was initially abstracted in a standardized
manner from the TCC biorepository system (TransMed,
115121
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Cupertino, CA). Data abstracted included demographic
variables (date of birth, gender, race, and ethnicity) as well
as clinical information [medical record numbers (MRNs),
date of diagnosis, primary site at diagnosis, histology, first
course of treatment, multi-targeted TKI received, start
and stop date of TKI, and date of death or last follow-up].
Sources for these data were the Florida Cancer Registry
and electronic medical records. Information abstracted
from TransMed was used to guide manual chart reviews.
Two clinicians and researchers performed
independent manual chart reviews using the patients’
MRNs. Chart reviews included the validation of
information generated using TransMed abstraction
and manual review of patients’ clinical notes and
imaging (PET/CT/MRI) results before and after TKI
administration. Data collected included radiologists’ and
clinicians’ impressions of disease before and after TKI
initiation (e.g., stable vs. progressive vs. responding,
based on imaging studies) and time to drug change or
discontinuation. Physicians’ recommendations at first
imaging follow-up (generally 2-3 months post-initiation)
were used to identify patients intrinsically resistant to
multi-targeted TKIs. The decision to stop TKI therapy due
to cancer progression on imaging studies was classified as
intrinsic resistance. Patients who continued TKI therapy
due to response, stable disease, or mixed response on first
imaging follow-up, and patients who met these criteria
but stopped therapy due to side effects were classified
as non-resistant. Individuals who stopped therapy early
due to side effects or were lost to follow-up (i.e., those
without first-imaging follow-up) could not confidently be
classified were excluded from analyses. Based on these
data, reviewers documented their individual impressions
of patients as either resistant or non-resistant. Phenotype
classifications were then compared and a third reviewer, a
medical oncologist experienced with TKI prescribing and
follow-up, provided adjudication when necessary.

Next-generation sequencing and copy number
alterations
WES was performed in order to identify somatic
mutations in the coding regions of the human genome.
Briefly, 200 ng of DNA, as quantified by qPCR, was
used as input for library preparation with the SureSelectXT
Reagent Kit (Agilent, Santa Clara, CA). For each tumor
DNA sample, a genomic DNA library was constructed
according to the SureSelectXT Target Enrichment for
Illumina Multiplexed Sequencing (#G7530-90000)
protocol (Agilent), including the suggested modifications
for FFPE-derived DNA samples. The pre-captured library
was amplified, and the size and quality of the library was
evaluated using a 2100 BioAnalzyer (Agilent) and Qubit™
quantification (Thermo Fisher Scientific, Waltham, MA).
Approximately 500 to 750 ng of pre-captured library was
used for hybridization at 65°C for 24 hr. Hybridization and
www.impactjournals.com/oncotarget

target enrichment were conducted using the SureSelectXT
Clinical Research Exome kit (Agilent). The postcaptured library was amplified and evaluated with a 2100
Bioanalyzer (Agilent). The enriched library was quantified
using a Library Quantification Kit for NGS (KAPA
Biosystems, Wilmington, MA), and samples were diluted
to a 4 nM concentration. Denaturation was conducted
using NaOH, followed by neutralization with Tris buffer
pH 8.5, and samples were diluted to a concentration of 20
pM in HT1. Next, samples were diluted to concentrations
between 1.7 pM to 2.2 pM for sequencing with a v2
sequencing reagent kit and a NextSeq 500 desktop
sequencer (Illumina, San Diego, CA). Approximately 85
million 75 base paired-end reads were generated for each
DNA sample.
Individuals with targeted gene sequencing data
available had sequencing performed previously through
collaboration with the Beijing Genomics Institute
(Shenzhen, China). Briefly, tumor samples underwent
targeted gene sequencing using a custom SureSelect
platform (Agilent, Santa Clara, CA) targeting 1,321
cancer-related genes and 2 x 90bp massively parallel
sequencing using a Genome Analyzer IIx (Illumina, San
Diego, CA). In order to identify whole genome CNA and
loss-of-heterozygosity, the OncoScan® FFPE Assay Kit
(Affymetrix, Santa Clara, CA) was used according to the
manufacturer’s protocol, with an input of 80 ng of FFPEextracted DNA.

Candidate gene selection
To decrease multiple comparison correction and
increase the likelihood of identifying biologically plausible
associations, we utilized a candidate gene approach for
analysis. Candidate genes included genes known to be
important in solid tumor biology and anticancer drug
response were selected utilizing the overlapping genes
reported on clinical cancer genetic testing platforms (such
as FoundationOne®) and those captured with the targeted
sequencing platform designed specifically for the TCC
study cohort (Supplementary Table 1).

Data quality control and variant detection
Whole exome sequencing reads were aligned to
the reference human genome (hs37d5) with the BurrowsWheeler Aligner [57], and duplicate identification,
insertion/deletion realignment, quality score recalibration,
and variant identification were performed with Picard
(Broad Institute, http://broadinstitute.github.io/picard/)
and the Genome Analysis ToolKit (GATK) v2.2-Lite
[58]. Genotypes were determined across all samples at
variant positions. Sequence variants were annotated to
determine genic context (i.e., non-synonymous, missense,
splicing) using ANNOVAR [59], and summarized using
spreadsheets and a genomic data visualization tool,
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VarSifter [60]. Additional contextual information from
other studies was added, including allele frequency from
1000 Genomes [61] and the NHLBI Exome Sequence
Project [62], in silico function impact predictions
(PolyPhen and SIFT), and observed impacts from
databases including ClinVar (NCBI, http://www.ncbi.
nlm.nih.gov/clinvar/), the Catalogue of Somatic Mutations
in Cancer (COSMIC) [63], and The Cancer Genome
Atlas (TCGA, https://cancergenome.nih.gov/). Somatic
mutations were prioritized by excluding variants observed
in 1000 Genomes [61] and variants observed at >5% in an
internal dataset of adjacent normal (i.e., non-tumor) tissue.
Variants with GATK variant quality score recalibration
(VQSR) tranche > 99.9 or genotype quality (GQ) < 15
were excluded.
The CNA data generated was analyzed using Nexus
Copy Number™ 6.0 software (BioDiscovery, El Segundo,
CA) utilizing the TuScan™ algorithm, specifically
designed for OncoScan® FFPE Assay data [64]. The
estimated CNA regions were annotated with the reference
human genome (hg19) and the evaluation of array
performance was measured using default criteria (MAPD
≤ 0.3 and ndSNPQC ≥ 26). Plots of whole genome CNAs
and minor (or B) allele frequencies (BAFs) were generated
for each individual. Briefly, the BAF was calculated as the
count of minor (B) alleles (A/T) divided by the total count
of major (A) (G/C) and minor (B) alleles [65]. Using the
TuScan™ algorithm the average CNA of all cells within
each sample was generated. Genes with 70% or greater
overlap in copy number aberrant regions were classified as
being altered. Copy number gains greater than seven and
homozygous losses were considered potentially clinically
significant, as is standard in clinical tumor testing, and
included in analyses.

further analyses. The two-tailed Fisher’s exact test
was used to test the statistical significance of mutated
candidate genes identified in resistant and non-resistant
patients. An FDR-corrected p-value < 0.1 was considered
statistically significant, and an uncorrected p-value < 0.1
was significant for exploratory associations. Cytoscape
(v.3.4.0) Enrichment Map [66] was utilized to conduct
gene set enrichment of top gene hits, and the Genomics in
Drug Sensitivity in Cancer database [67] was utilized to
explore in vivo-derived predictions of sensitivity to multitargeted TKIs based on mutation status of the top hits.
For CNA analysis, copy number gains and losses
were grouped. Presence of copy number aberrations
between resistant and non-resistant individuals were
arranged in contingency tables and analyzed using a twosided Fisher's exact test. FDR-corrected p-values < 0.1
were considered statistically significant, and a threshold of
FDR-corrected p < 0.3 was used for exploratory analysis
[68, 69]. Cytoscape (v.3.4.0) Enrichment Map [66] was
utilized to conduct gene set enrichment of top gene hits.
Statistical analysis was conducted using the opensource, statistical programming language, R (version 3.3.2)
[70]. CNA and WES data were combined to build a model
leveraging both technologies. CNAs were annotated as 1,
0, -1 for gain, no change, or loss, respectively, based on
the criteria described above. Subjects with >20% missing
data and genes with >5% missing data were excluded from
further analysis. Remaining missing genes were imputed
using the mean of the study cohort. Subsequently, feature
reduction, via a random forest model was constructed
using 2000 trees and 12 features at each split [71]. CNA
and WES features with a mean decrease in Gini score
>0.2, as determined using the elbow method, were selected
for inclusion in the decision tree classification model using
recursive partitioning trees [72]. Figures were generated
using R (version 3.3.2) and GraphPad Prism 6.

Data analysis
Patients were classified into one of two cohorts:
(1) resistant or (2) non-resistant using the phenotyping
methods described above. Descriptive statistics were used
to summarize demographic and clinical characteristics of
patients included. Means, standard deviations and ranges
were calculated for continuous variables, and frequencies
and percentages were generated for categorical variables.
As a conservative approach and where applicable, nonparametric statistical tests were implemented to avoid
assuming the data was normally distributed. Demographic
and clinical characteristic comparisons between resistant
and non-resistant patients were performed using twotailed Fisher’s exact tests for categorical variables and
the Mann-Whitney U test for continuous variables.
Batch effects between the two sequencing methods and
differences between tumor types were detected using
a two-tailed Fisher’s exact test and, when comparing
between sequencing platforms, mutated genes with
an FDR-corrected p-value < 0.05 were excluded from
www.impactjournals.com/oncotarget
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